Anti-HBeAg Intrabody [Tat] (IAB-B037(T))
Recombinant anti-HBeAg intrabody in fusion with HIV Tat works within cells to bind HBeAg, expressed in E. coli cells. The development of new therapies that target viral proteins, such as HBeAg, which regulates of the immune system, may offer a new wave of potential therapeutics to circumvent progression to CHB and liver disease.
Specifications
- Immunogen
- hepatitis B e antigen
- Host
- llama
- Type
- vhh-Tat
- Cell Penetrating Peptide
- TAT
TAT was able to deliver different proteins, such as horseradish peroxidase and RNase A across cell membrane into the cytoplasm in different cell lines in vitro. The size range of proteins with effective delivery is from 30kDa to 120-150kDa. In one study, TAT-fused proteins are rapidly internalized by lipid raft−dependent macropinocytosis using a transducible TAT−Cre recombinase reporter assay on live cells. In another study, a TAT-fused protein was delivered into mitochondria of breast cancer cells and decreased the survival of breast cancer cells, which showed capability of TAT-fusion proteins to modulate mitochondrial function and cell survival. However, very few in vivo studies have succeeded. In one study, in vivo delivery of TAT- or penetratin-crosslinked Fab fragments yielded varied organ distributions and an overall increase in organ retention, which showed tissue localization.
- Species Reactivity
- HBV
- Applications
- Can be useful in applications such as: Enzyme-linked Immunosorbent Assay; Western blot; Immunocytochemistry; Functional studies
Target
- Alternative Names
- HBeAg; hepatitis B e antigen; Core antigen; Core protein antibody; HBe antigen; HBeAg; HBVgp4; Pre C,C
For lab research use only, not for diagnostic, therapeutic or any in vivo human use.
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email: